Supernus Pharmaceuticals Inc

詳細情報 Supernus Pharmaceuticals Inc 企業名

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Supernus Pharmaceuticals Incの企業情報



企業コードSUPN

会社名Supernus Pharmaceuticals Inc

上場日Dec 28, 2010

最高経営責任者「CEO」Mr. Jack A. Khattar

従業員数674

証券種類Ordinary Share

決算期末Dec 28

本社所在地9715 Key West Avenue

都市ROCKVILLE

証券取引所NASDAQ Global Market Consolidated

国United States of America

郵便番号20850

電話番号13018382500

ウェブサイトhttps://www.supernus.com

企業コードSUPN

上場日Dec 28, 2010

最高経営責任者「CEO」Mr. Jack A. Khattar

Supernus Pharmaceuticals Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.21M

+2.76%

Mr. Frederick M. Hudson, CPA

Independent Director

46.31K

-13.87%

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

22.57K

--

Dr. Georges Gemayel, Ph.D.

Independent Director

18.68K

--

Mr. Frank Mottola

Chief Operating Officer, Chief Technology Officer

15.15K

--

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

13.37K

+5.27%

Dr. Jonathan Rubin, M.D.

Senior Vice President, Chief Medical Officer - Research and Development

10.67K

+10.74%

Mr. Timothy C. (Tim) Dec, CPA

Chief Financial Officer, Senior Vice President

901.00

-92.89%

Mr. Charles W. Newhall, III

Independent Chairman of the Board

--

Ms. Bethany L. Sensenig

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.21M

+2.76%

Mr. Frederick M. Hudson, CPA

Independent Director

46.31K

-13.87%

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

22.57K

--

Dr. Georges Gemayel, Ph.D.

Independent Director

18.68K

--

Mr. Frank Mottola

Chief Operating Officer, Chief Technology Officer

15.15K

--

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

13.37K

+5.27%

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Net product sales-Qelbree

77.55M

46.87%

Net product sales - GOCOVRI

36.66M

22.16%

Net product sales-APOKYN

12.82M

7.75%

Net product sales- Oxtellar XR

11.64M

7.03%

Net product sales- Trokendi XR

11.19M

6.77%

他の

15.60M

9.43%

地域別USD

会社名

収益

比率

United States

165.45M

100.00%

事業別

地域別

事業別USD

会社名

収益

比率

Net product sales-Qelbree

77.55M

46.87%

Net product sales - GOCOVRI

36.66M

22.16%

Net product sales-APOKYN

12.82M

7.75%

Net product sales- Oxtellar XR

11.64M

7.03%

Net product sales- Trokendi XR

11.19M

6.77%

他の

15.60M

9.43%

株主

更新時刻: Fri, Aug 15

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

13.97%

The Vanguard Group, Inc.

10.52%

Armistice Capital LLC

8.39%

Dimensional Fund Advisors, L.P.

5.27%

Macquarie Investment Management

4.82%

他の

57.03%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

13.97%

The Vanguard Group, Inc.

10.52%

Armistice Capital LLC

8.39%

Dimensional Fund Advisors, L.P.

5.27%

Macquarie Investment Management

4.82%

他の

57.03%

種類

株主統計

比率

Investment Advisor

52.68%

Investment Advisor/Hedge Fund

29.42%

Hedge Fund

17.15%

Individual Investor

4.28%

Research Firm

2.30%

Pension Fund

1.59%

Venture Capital

1.47%

Bank and Trust

0.67%

Sovereign Wealth Fund

0.10%

機関投資家保有株



更新時刻: Wed, Oct 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q3

575

60.19M

104.97%

-3.36M

2025Q2

565

63.61M

113.46%

-2.51M

2025Q1

587

64.77M

115.71%

-2.86M

2024Q4

569

65.17M

116.92%

-2.59M

2024Q3

551

65.02M

117.72%

-2.14M

2024Q2

536

63.49M

115.33%

-2.27M

2024Q1

535

61.47M

111.83%

-3.83M

2023Q4

534

61.60M

112.54%

-3.30M

2023Q3

534

60.88M

111.42%

-4.46M

2023Q2

534

61.11M

111.93%

-1.60M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

8.01M

14.29%

-191.39K

-2.33%

Jun 30, 2025

The Vanguard Group, Inc.

6.19M

11.04%

+41.36K

+0.67%

Jun 30, 2025

Armistice Capital LLC

4.81M

8.58%

-384.00K

-7.39%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

3.02M

5.39%

+117.48K

+4.05%

Jun 30, 2025

Macquarie Investment Management

2.76M

4.93%

+62.46K

+2.31%

Jun 30, 2025

Khattar (Jack A)

2.15M

3.84%

+54.63K

+2.60%

Sep 30, 2025

State Street Investment Management (US)

2.21M

3.94%

+63.21K

+2.95%

Jun 30, 2025

Renaissance Technologies LLC

1.66M

2.95%

+69.60K

+4.39%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.40M

2.5%

+72.99K

+5.50%

Jun 30, 2025

Stephens Investment Management Group, LLC

1.58M

2.82%

-157.39K

-9.05%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

詳細情報 Supernus Pharmaceuticals Inc 企業名

Supernus Pharmaceuticals Incの企業情報

Supernus Pharmaceuticals Incの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割